Automated platform for cell therapy manufacturing at scale

Limula SA is based in Lausanne, Switzerland, looking to disrupt the status quo in the manufacturing of Cell & Gene Therapies. The company brings a novel approach to automation, offering the biopharma industry a fully autonomous, end-to-end platform—much like a nespresso machine for cell therapy production. Their mission is to support rapid and cost-effective introduction of new advanced therapy products to the market. Their platform leverages a proprietary combination of hardware, consumable and software to bring all functionalities required for on-demand and at-scale manufacturing of cell therapies in a single device. With its revolutionary solution, Limula is unlocking a nascent market that has grown from $150m to $2.5B+ between 2018 and 2024, and yet has less than 10% penetration today.